Dynamic MapReport

World News   USA   California   Bay Area   San Francisco   South SF   Genentech   Roche (16)
Genentech, Roche Timeline Tuesday, April 24 Bookmark and Share     Author
Search Bay Area News Atlas:
Roche-Genentech deal called close
World News (12) World Business (847) USA (336) California (187) Bay Area (12) Bay Area Business (1699) San Francisco (2214) South SF (135) Genentech (71) Roche (16)
2014 (3) 2009 (8) 2008 (5)
Genentech Roche on Wikipedia Genentech Roche on Web

Brisbane Business (16)   Brisbane Bio Tech (10)   Genentech Business   South SF Merger and Acquisition (19)
Genentech to buy Seragon Pharmaceuticals  Genentech, which is part of Roche, will pay for a San Diego company developing treatments for the most common kind of breast cancer Roche buys Mountain View startup for $350 million  Swiss pharmaceutical giant will pay for Genia Technologies, a start-up that will expand Roche’s gene-sequencing capabilities Roche completes purchase of Genentech  Swiss drugmaker completed its acquisition of biotechnology pioneer by sweeping up enough shares through an offer to gain ownership of 93% Roche touts Herceptin in stomach cancers  A leading Genentech breast cancer drug also prolongs patient survival in certain forms of stomach cancer Roche to take over Genentech for $47B
Roche buys Brisbane drugmaker InterMune for $8.3 billion

year 2014 Top ^

  Swiss pharmaceutical giant is expanding its respiratory disease treatments by acquiring InterMune at $74 per share in an all-cash transaction

year 2009 Top ^

  Swiss giant agreed to buy the 44% of biotech pioneer that it doesn't already own, ending a long corporate struggle
 The $95-per-share deal brings Roche all of the sales of cancer drugs as well as its promising research pipeline. The deal offers $95 per share for the 44 percent of Genentech that Roche Holding AG doesn't already own

  Roche is reportedly willing to pay Genentech $95 a share, up from the $93, in what would be a $46.7 billion deal
Mar.6 Roche raises bid for Genentech
  Swiss drugmaker increased its offer to $93 per share. Genentech shares shot up to $90.05, gaining $8.41 or 10 percent
Mar.3 Genentech replies to hostile Roche bid  Genentech's management fired off figures about its future growth to persuade investors and analysts that the Swiss drug giant is selling it short Feb.6 Roche CEO: Offer for Genentech fair deal  Severin Schwan the company's surprisingly low hostile $86.50-per-share offer is fairly priced and he is confident to get enough financing Jan.30 Roche revives takeover bid of Genentech
  Swiss drugmaker, frustrated by stalled negotiations, plans a hostile takeover at a lower price than the $89 per share rejected in August

year 2008 Top ^

Aug.17 Recruiters eye Genentech employees  While Roche mulls whether to raise its offer price for biotechnology powerhouse, many prized Genentech professionals Aug.13 Genentech rejects Roche's $43.7b bid
  Biotechnology giant rejected a buyout offer from its majority owner Roche but said it is open to a higher takeover bid Jul.31 Shareholders sue to halt Roche buyout  Shareholders' attorneys are asking a court to invalidate long-standing agreements between Genentech and its majority owner Jul.25 Panel to ponder Roche takeover offer  Genentech has set up a committee of independent directors to consider Swiss drugmaker offer to acquire all shares it does not already own Jul.21 Roche Offers $44B For Remaining Shares  Roche Holding, which already owns 55.9%, was offering $43.7 billion to take over the remaining shares of Genentech

Add a favorite (file a bookmark) to Genentech, Roche Timeline

Please send feedback to: support@mapreport.com

Advertise on Genentech, Roche Page